Ishita Drugs & Industries Ltd shareholders approved the audited financial statements for the fiscal year ended March 31, 2026, during the company's 33rd Annual General Meeting (AGM) held on September 30, 2026. The meeting also sanctioned the appointment of statutory auditors for the 2026-27 fiscal year.

The AGM took place at Hotel Krsna Lila in Sanand, Gujarat, with 32 members attending in person. Chairman Jagdishprasad Agrawal briefed attendees on the company's financial performance for FY26 and provided updates on the ongoing upgradation project of its manufacturing facility.

Key resolutions passed

Members voted to adopt several ordinary and special resolutions as outlined in the meeting notice:

• Adoption of Financial Statements: Approval of audited accounts for FY26 along with Board and Auditor reports.
• Auditor Appointment: Appointment of auditors for the 2026-27 period with remuneration fixed by the Board.
• Director Re-appointment: Special resolution to re-appoint Mrs. Abha Agrawal (DIN: 01589479) as a Non-Executive Non-Independent Director post-75 years of age.
• Related Party Transactions: Ordinary resolutions approving transactions with Ishita Pharmaceuticals and Anvi Lifesciences Private Limited.

Voting process and attendance

The company facilitated voting through NSDL e-voting from September 27 to September 29, 2026, alongside physical ballot papers for those present. Meenu Maheshwari, a practicing company secretary, served as the scrutinizer. The consolidated voting results were scheduled for declaration within 48 hours of the meeting's conclusion.

Ishita Drugs & Industries Ltd has closed its trading window for designated persons starting October 1, 2026. The restriction remains in effect until 48 hours after the company declares its unaudited financial results for the quarter ended September 30, 2026.

This action is taken pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct. These regulations mandate that insiders refrain from dealing in securities during periods when price-sensitive information is likely to be disclosed.

Regulatory Compliance and Timeline

The closure applies to all Designated Persons of the company as defined under the regulatory framework. The specific dates for the blackout period are outlined below:

The Managing Director, Jagdish Agrawal, signed the intimation submitted to BSE Limited on September 26, 2026. This filing ensures that all market participants are aware of the restrictions on insider trading during the sensitive period leading up to the earnings announcement.